Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 853 currently available and novel biosimilar products, detailing information about the region(s) and their clinical phase of development. Additionally, we provide estimates for biosimilar launches in the seven major markets (United States, EU5, and Japan), as well as aggregate statistics to help answer key competitive intelligence questions. The Emerging Biosimilars Landscape is updated quarterly.
Questions Answered in This Report:
- How many biosimilar candidates are currently undergoing Phase I or III clinical development in a particular region?
- Which biologic classes and reference molecules are most frequently targeted by biosimilars developers?
- Which are the top 10 biosimilars developers by number of clinical stage candidates?
- When is the expected launch date for late stage pipeline candidates in the seven major markets?
- What is the level of competition expected for a brand, globally and by region/country?
Scope:
- Markets covered: Global
- Secondary research: clinical trial registries, company pipelines, annual reports, news articles, company press releases and presentations.
Mentioned in This Report:
Key Companies Mentioned
- Amgen
- Allergan
- Biocon
- Celltrion
- Dr. Reddy’s
- Fresenius Kabi
- Gedeon Richter
- Intas
- Merck & Co
- Viatris
- Pfizer
- Samsung Bioepis
- Sandoz
- Shanghai Henlius Biotech
Key Drugs Mentioned
- Aranesp
- Avastin
- Darzalex
- Enbrel
- Erbitux
- Eylea
- Forteo
- Herceptin
- Humira
- Keytruda
- Lantus
- Lucentis
- Neulasta
- Neupogen
- Opdivo
- Prolia / Xgeva
- Remicade
- Rituxan / MabThera
- Xolair
Table of contents
- Biosimilars - Emerging Biosimilars - Emerging Biosimilars Landscape
- Emerging Biosimilars Landscape
- Global Biosimilars Pipeline
- Biosimilars Pipeline Analysis
- Biosimilars Development Pipeline by Phase of Development
- Biosimilars Development Pipeline by Phase of Development
- Biosimilars Development Pipeline by Class
- Biosimilars Development Pipeline by Class
- Biosimilar Activity Corresponding to Key Reference Molecules
- Biosimilar Activity Corresponding to Key Reference Molecules
- Leading Biosimilars Developers
- Top Biosimilars Developers by Number of Biosimilars in the Major Markets
- Top Biosimilars Developers by Number of Biosimilars outside the Major Markets
- Top Geographies by Number of Biosimilars Under Clinical Development
- Top Geographies by number of biosimilars Under Clinical Development
- Biosimilar Launch Dates
- Appendix
- Emerging Biosimilars Landscape
Related Market Assessment Reports
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric ADHD (US)
ADHD is a common pediatric neurodevelopmental disorder, with diagnosis rates supported by increased awareness and routine screening; however, symptoms often persist into adulthood. Longacting…
